Procalcitonin as a biomarker in respiratory tract infection

Clinical Infectious Diseases

Volumn 52, Issue SUPPL. 4, 2011, Pages

  Gilbert, David N ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; GAMMA INTERFERON; PROCALCITONIN;

ADENOVIRUS; ANTIMICROBIAL THERAPY; ARTICLE; BACTERIAL PNEUMONIA; BACTERIUM DETECTION; CHLAMYDOPHILA PNEUMONIAE; COMMUNITY ACQUIRED PNEUMONIA; DIAGNOSTIC TEST ACCURACY STUDY; EMPYEMA; HAEMOPHILUS INFLUENZAE; HUMAN; IMMUNOASSAY; INFLUENZA VIRUS; INNATE IMMUNITY; LEGIONELLA PNEUMOPHILA; METAPNEUMOVIRUS; MULTIPLEX POLYMERASE CHAIN REACTION; MYCOPLASMA PNEUMONIAE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REAL TIME POLYMERASE CHAIN REACTION; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY TRACT INFECTION; RHINOVIRUS; SENSITIVITY AND SPECIFICITY; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES; TREATMENT RESPONSE; VIRAL RESPIRATORY TRACT INFECTION;

BACTERIAL INFECTIONS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CALCITONIN; CLINICAL LABORATORY TECHNIQUES; DRUG MONITORING; HUMANS; PROTEIN PRECURSORS; RESPIRATORY TRACT INFECTIONS;

EID: 79953783400     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cir050     Document Type: Article

References (34)

1. Schuetz P, ChristCrain M, Muller B. Biomarkers to improve di-agnostic and prognostic accuracy in systemic infection. Curr Opin Crit Care 2007; 13:578-85. (Pubitemid 47357461)
2. ChristCrain M, Muller B. Biomarkers in respiratory tract infections: diagnostic guides to antibiotic prescription, prognostic markers and mediators. Eur Resp J 2007; 30:556-73. (Pubitemid 351182082)
3. Becker KL, Snider R, Nylen ES. Procalcitonin assay in systemic in-flammation, infection, and sepsis: clinical utility and limitations. Crit Care Med 2008; 36:941-52.
4. Becker KL, Nylen ES, White JC, et al. Procalcitonin and the calcitonin gene family ofpeptides in inflammation, infection, and sepsis: a jour-ney from calcitonin back to its precursors. J Clin Endocrinol Metab 2004; 89:1512-25. (Pubitemid 38507896)
5. Muller B, White JC, Nylen ES, et al. Ubiquitous expression of the calcitonin-I gene in multiple tissues in response to sepsis. J Clin En-docrinol Metab 2001; 86:396-404. (Pubitemid 32109825)
6. Linscheid P, Seboek D, Nylen ES, et al. In vitro and in vivo calcitonin I gene expression in parenchymal cells: a novel product of human adi-pose tissue. Endocrinology 2003; 144:5578-84. (Pubitemid 37476087)
7. Nylen ES, Whang KT, Snider RH Jr., et al. Mortality is increased by procalcitonin and decreased by an antiserum reactive to procalcitonin in experimental sepsis. Crit Care Med 1998; 26:1001-6. (Pubitemid 28272848)
8. Thai KT, Chan ES, Ling KL, et al. Role of procalcitonin in infectious gastroenteritis and inflammatory bowel diease. Dig Dis Sci 2008; 53:2960-8.
9. Hugle T, Schuetz P, Muller B, et al. Serum procalcitonin for discrim-ination between septic and nonseptic arthritis. Clin Exper Rheumatol 2008; 26:453-6. (Pubitemid 352003215)
10. Chen D-Y, Chen Y-M, Ho W-L, et al. Diagnostic value of procalcitonin for differentiation between bacterial infection and noninfectious in-flammation in febrile patients with active adultonset Still's disease. Ann Rheum Dis 2009; 68:1074-5.
11. Scire CA, Perotti C, Bruschi E, et al. Diagnostic value of procalcitonin measurement in febrile patients with systemic autoimmune diseases. Clin Exper Rheum 2008; 26:453.
12. Perren A, Cerutti B, Lepori M, et al. Influence of steroids on procalcitonin and C-reactive protein in patients with COPD and communityacquired pneumonia. Infection 2008; 36:163-6.
13. Preas HL, Nylen ES, Snider RH, et al. Effects of antiinflammatory agents on serum levels of calcitonin precursors during experimental endotoxemia. J Infect Dis 2001; 184:373-6. (Pubitemid 32662188)
14. Schültzle H, Forster J, SupertiFurga A, et al. Is serum procalcitonin a reliable diagnostic marker in children with acute respiratory tract infections. Eur J Pediatr 2009; 168:1117-24.
15. Walsh E, Falsey A, Nylen E, et al. Serum biomarker measurements in adults with viral infections Abstract D-2258, ICAAC 2008.
16. Melendi GA, Laham FR, Monsalvo C, et al. Cytokine profiles in the respiratory tract during primary infection with human meta-pneumovirus, respiratory syncytial virus or influenza virus in infants. Pediatrics 2007; 120:e410-5. (Pubitemid 47219492)
17. Morgenthaler NG, Struck J, Fischer-Schulz C, et al. Sensitive im-munoluminometric assay for the detection ofprocalcitonin. Clin Chem 2002; 48:788-90. (Pubitemid 34439119)
18. Struck J, Strebelow M, Tietz S, et al. Methods for the selective mea-surement of aminoterminal variants of procalcitonin. Clin Chem 2009; 55:1672-9.
19. Sato M, Hosoya M, Wright PF. Differences in serum cytokine levels between influenza virus A and B infections in children. Cytokine 2009; 47:65-8.
20. Lee YM, Miyahara N, Takeda K, et al. IFNgamma production during initial infection determines the outcome of reinfection with respiratory syncytial virus 2008; 177:208-18.
21. ChristCrain M, Jaccard-Stolz D, Bingisser R, et al. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections. Lancet 2004; 363:600-7.
22. ChristCrain M, Stolz D, Bingisser R, et al. Procalcitonin guidance of antibiotic therapy in communityacquired pneumonia. Am J Crit Care Med 2006; 174:84-93. (Pubitemid 43955248)
23. Stolz D, ChristCrain M, Bingisser R, et al. Antibiotic treatment of exacerbations ofCOPD. Chest 2007; 131:9-19.
24. Briel M, ChristCrain M, Young J, et al. Procalcitoninguided antibiotic use versus a standard approach for acute respiratory tract infections in primary care. BMC Fam Pract 2005; 6:34.
25. Kristofferson KB, Sogaard OS, Wejse C, et al. Antibiotic treatment interruption of suspected lower respiratory tract infections based on a single procalcitonin measurement at hospital admission\a ran-domized trial. Clin Microbiol Infect 2009; 15:481-7.
26. Schuetz P, ChristCrain M, Thomann R, et al. Effect ofprocalcitonin-based guidelines vs. standard guidelines on antibiotic use in lower respiratory tract infections. The ProHOSP Randomized Controlled Trial. JAMA 2009; 302:1059-66.
27. Lin M-C, Chen Y-C, Wu J-T, et al. Diagnostic and prognostic values of pleural fluid procalcitonin in parapneumonic pleural effusions. Chest 2009; 136:205-11.
28. Porcel JM, Vines M, Gao G, et al. Biomarkers of infection for the differential diagnosis ofpleural effusions. Eur Respir J 2009; 34:1383-9.
29. Nolte FS. Molecular diagnostics for detection of bacterial and viral pathogens in communityacquired pneumonia. Clin Infect Dis 2008; 47:S123-S126.
30. Pabbaraju K, Tokaryk KL, Wong S, et al. Comparison of the Luminex xTAG respiratory virus panel with inhouse nucleic acid amplification tests for diagnosis of respiratory virus infections.J Clin Microbiol 2008; 46:3056-62.
31. Morozumi M, Nakayana E, Iwata S, et al. Simultaneous detection of pathogens in clinical samples from patients with communityacquired pneumonia by realtime PCR with pathogenspecific molecular beacon probes.J Clin Microbiol 2006; 44:1440-6.
32. Murdoch DR, O'Brien KL, Scott JA, et al. Breathing life into molecular diagnostics. J Clin Microbiol 2009; 47:3405-8.
33. Johansson N, Kalin M, TiveljungLindell A, et al. Etiology of com-munityacquired pneumonia: increased microbiological yield with new diagnostic methods. Clin Infect Dis 2010; 50:202-9.
34. Gilbert DN. Use of plasma procalcitonin levels as an adjunct to clinical microbiology. J Clin Microbiol 2010; 48:2325-9.